Report : Middle East and Africa Label Free Detection Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Instruments and Consumables), Technology (Surface Plasmon Resonance, Bio-Layer Interferometry, Isothermal Titration Calorimetry, Differential Scanning Calorimetry, and Other LFD Technologies), Application (Binding Kinetics, Binding Thermodynamics, Endogenous Receptor Detection, Hit Confirmation, Lead Generation, and Other Applications), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations, and Other End Users)
The pharmaceutical and biotechnology companies segment by end user is estimated to lead the market growth during the forecast period.
According to a new market research study of “Middle East and Africa Label Free Detection Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Technology, Application, End User and Country.” The Middle East and Africa label free detection market is expected to reach US$ 37.25 million by 2028 from US$ 22.32 million in 2021; it is estimated to grow at a CAGR of 7.6% from 2021 to 2028. The report highlights trends prevailing in the Middle East and Africa label free detection market and the factors driving market along with those that act as hindrances.
Direct partnerships of pharmaceutical and biotechnology companies with academic centers are becoming prevalent. For academic and pharmaceutical researchers, the benefits of these partnerships are evident. Financial support from pharmaceutical companies provides steady funding and increases the probability of impactful work. These collaborations may begin with funding for academic research for promising candidates. The strategy helps pharmaceutical companies fill gaps in their portfolios at lower costs and risks. The growing number of such drug discovery programs through academic–industrial partnerships propels the growth of the label free detection market.
The practice of outsourcing biotechnology and pharmaceutical services is becoming more popular due to the effects of the COVID-19 pandemic, and the rise in drug development costs and R&D investments. Pharmaceutical companies are increasingly outsourcing research activities to academic and private contract research organizations (CROs) to stay competitive and flexible in the world of exponentially growing knowledge, increasingly sophisticated technologies, and an unstable financial environment.
Therefore, a rise in pharmaceutical outsourcing fuels the growth of the label free detection market in the Middle East and Africa.
The Middle East and Africa label free detection market based on the product is segmented into instruments and consumables. Based on technology, the Middle East and Africa label free detection market is segmented into surface plasmon resonance, bio-layer interferometry, isothermal titration calorimetry, differential scanning calorimetry, and other LFD technologies. The Middle East and Africa label free detection market, based on application is segmented into binding kinetics, binding thermodynamics, endogenous receptor detection, hit confirmation, lead generation, and other applications. The Middle East and Africa label free detection market, based on end user is segmented into pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations and other end users. Geographically, the Middle East and Africa label free detection market can be divided into UAE, Saudi Arabia, South Africa and Rest of Middle East and Africa.
General Electric, Perkin Elmer, Inc., AMETEK Inc., F. HOFFMANN-LA ROCHE LTD., Spectris, Agilent Technologies, Inc., Sartorius AG, and Corning Incorporated are among the leading companies operating in the Middle East and Africa label free detection market.
Contact Person: Sameer Joshi
Email Id: email@example.com